Purdue Pharma secured court approval for a $125 million settlement with McKinsey & Co. to resolve claims related to the firm’s advisory role in marketing the drugmaker’s opioids.

Type to search articles, cases, and authors. Press ↵ to view all results. The bankruptcy code does not authorize a release and injunction that, as part of a plan of reorganization under Chapter 11, ...

By Dietrich Knauth NEW YORK, May 1 (Reuters) - Purdue Pharma said on Friday that it has ceased operations and concluded its ...

Nearly 140,000 people filed claims against the company for the harm they said its drugs caused. Fewer than half of them will get any compensation.

Purdue Pharma, the bankrupted drug manufacturer at the center of the nation’s yearslong opioid epidemic, shut down May 1. The ...

Newark, New Jersey - A federal judge on Tuesday criminally sentenced OxyContin-maker Purdue Pharma over its role in the opioid crisis, ahead of upcoming bankruptcy proceedings and its dissolution.

Justin Winerman of BCLP explains that nonconsensual third-party releases remain available under Chapter 15, despite the ...

On March 31, 2026, US District Court Chief Judge Colm F. Connolly of the District of Delaware affirmed a bankruptcy court order recognizing ...

NEW YORK, April 9 (Reuters) - Consulting firm McKinsey & Co has agreed to contribute $125 million to Purdue Pharma's bankruptcy settlement, resolving potential legal claims over advice it provided ‌to ...